Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals (GB:HIK)
:HIK
HIK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,750.00p - 2,360.00p
Previous CloseN/A
Volume7.28K
Average Volume (3M)498.66K
Market Cap
£5.14B
Enterprise Value5.05B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)22.7
Beta0.83
Next Earnings
Feb 26, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 15, 2024Dividend Yield2.67%
Share Statistics
EPS (TTM)1.02
Shares Outstanding221,886,460
10 Day Avg. Volume491,805
30 Day Avg. Volume498,656
Standard Deviation0.08
R-Squared0.04
Alpha0.00721
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.12
Price to Cash Flow (P/CF)16.20
P/FCF Ratio22.30
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.59
Enterprise Value/Ebitda3.21
Forecast
1Y Price Target
2,489.17pPrice Target Upside7.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Hikma Pharmaceuticals News
PremiumCompany Announcements
Hikma Pharmaceuticals to Announce 2024 Financial Results
PremiumCompany Announcements
Hikma Pharmaceuticals Discloses PDMR Share Disposal
PremiumCompany Announcements
Hikma Pharmaceuticals Reappoints PwC as Auditor
PremiumCompany Announcements
Hikma Pharmaceuticals Projects Strong Growth for 2024
PremiumCompany Announcements
Hikma Pharmaceuticals Faces Shareholder Opposition on Buyback Waiver
PremiumCompany Announcements
Hikma Executives Invest in Company Shares
PremiumCompany Announcements
Hikma Pharmaceuticals Expands with Xellia Acquisition
PremiumCompany Announcements
Hikma Executive Sells Shares Worth £888.5K---
Bulls Say, Bears Say
Bulls Say
Business DevelopmentThe Generics business has secured a significant new long-term CDMO contract, which will help with greater utilization of its manufacturing facility.
Financial PerformanceHikma's trading update sees the business on track for its unchanged FY24 guidance and all divisions are trading as expected.
Bears Say
Market PerceptionProspects for growth and margin expansion within Branded are not fully appreciated, with potential for increased licensing opportunities.
---
Options Prices
Currently, No data available
---
Ownership Overview
7.66% Insiders
5.08% Mutual Funds
― Other Institutional Investors
78.58% Public Companies and
Individual Investors
HIK FAQ
What was Hikma Pharmaceuticals’s price range in the past 12 months?
Hikma Pharmaceuticals lowest share price was 1750.00p and its highest was 2360.00p in the past 12 months.
What is Hikma Pharmaceuticals’s market cap?
Hikma Pharmaceuticals’s market cap is £5.14B.
When is Hikma Pharmaceuticals’s upcoming earnings report date?
Hikma Pharmaceuticals’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Hikma Pharmaceuticals’s earnings last quarter?
Hikma Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported 1.007p earnings per share for the quarter, beating the consensus estimate of N/A by 1.007p.
Is Hikma Pharmaceuticals overvalued?
According to Wall Street analysts Hikma Pharmaceuticals’s price is currently Undervalued.
Does Hikma Pharmaceuticals pay dividends?
Hikma Pharmaceuticals pays a Annually dividend of 62.403p which represents an annual dividend yield of 2.67%. See more information on Hikma Pharmaceuticals dividends here
What is Hikma Pharmaceuticals’s EPS estimate?
Hikma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals have?
Hikma Pharmaceuticals has 221,886,460 shares outstanding.
What happened to Hikma Pharmaceuticals’s price movement after its last earnings report?
Hikma Pharmaceuticals reported an EPS of 1.007p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.261%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:HIK
---
Hikma Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
2,489.17p (7.38% Upside)
2,489.17p (7.38% Upside)
Blogger Sentiment
Bullish
GB:HIK Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth £64.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.08%
12-Months-Change
Fundamentals
Return on Equity
12.79%
Trailing 12-Months
Asset Growth
5.54%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals
Founded in the Middle East and with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, branded, and other, which comprise most of the company's revenue at about 41%, 33%, and 26%, respectively. About 62%, 33%, and 6% of Hikma's sales are based in the U.S., Middle East, North Africa, and Europe, and Other.
---
HIK Stock 12 Month Forecast
Average Price Target
2,489.17p
▲(7.38% Upside)
Technical Analysis
Best Analysts Covering HIK
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+8.07%
assigned a buy rating 7 months ago
Copying Peter Verdult's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +8.07% per trade.
---